Allkem General Discussion, page-4569

Down 18% in a month, should you buy up Allkem shares right now?We canvas the views of the experts…Bronwyn Alle
Allkem Ltd (ASX: AKE) shares are down 17.71% in a month, closing at $11.52 per share yesterday.Is this a prime buy-the-dip opportunity?Let's see what the experts say.
Are Allkem shares a buy?A number of brokers have commented on Allkem shares in the past fortnight.

Morgans says buy, Morgans has put an add rating on Allkem shares with an improved price target of $15.30.Analyst Max Vickerson said:Recent share price weakness means we see significant upside and upgrade our rating to 'add'.Allkem announced a range of cost increases across its portfolio of growth projects, whilst the company has also increased its long-term commodity price assumptions, boosting its estimated project values.Offsetting this, we now include Cauchari in our valuation which lifts our price target… after factoring in higher costs in James Bay and Sal de Vida.We note the higher risk for Allkem with a valuation dependent upon successfully delivering significant growth.
Macquarie tips 100% to 160% upsideMacquarie says Allkem and fellow ASX lithium shares Mineral Resources and Pilbara Minerals could have share price upside potential of between 100% to 160%.In The Australian on Wednesday, Macquarie commented:We see value in both Allkem and Liontown Resources, with Allkem offering unique exposure to both lithium brine in South America and spodumene production in Australia.
Allkem shares could go to $19 in a yearBell Potter currently has a buy rating and a $19 price target on Allkem stock.The broker says:In our view, the AKE-Livent Corporation merger will likely proceed and the merged entity will have an asset portfolio to support ongoing production and earnings growth into what we expect to be an exceptionally strong market for lithium.We expect the forthcoming Scheme Booklet to provide further clarity on the company's growth outlook when it is released in the coming months.

Bearish on lithium but bullish on AllkemGoldman Sachs is bearish on lithium prices but rates Allkem a buy with a $17.20 price target.It comments:With optionality across the Americas and Australia on the largest lithium resource in our coverage growing equity LCE production ~4x by FY28E, and at a discount to peers at ~1.0x NAV (peer average ~1.3x) and pricing ~US$990/t LT spodumene (peers ~US$1,200/t), Allkem remains our preferred lithium exposure. We maintain a Buy rating; 12m PT of A$17.2/sh.